Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-15
2005-02-15
Huang, Evelyn Mei (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S304000, C514S217070, C514S228500, C514S234500, C514S253040, C546S118000, C546S126000, C544S060000, C544S362000, C544S127000, C540S597000
Reexamination Certificate
active
06855724
ABSTRACT:
The present invention provides compounds of formula (I)wherein X, Y, R1, R2and R3are as defined hereinabove.The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors. Modulators of the CCR5 receptor may be useful in the treatment of various inflammatory diseases and conditions, and in the treatment of infection by HIV and genetically related retroviruses.
REFERENCES:
patent: 1118 858 (2001-07-01), None
patent: 0208071.1 (2002-04-01), None
patent: 0301575.7 (2003-01-01), None
patent: WO 9111172 (1991-08-01), None
patent: WO 9402518 (1994-02-01), None
patent: WO 9855148 (1998-12-01), None
patent: WO 9931099 (1999-06-01), None
patent: WO 0038680 (2000-07-01), None
patent: WO 0039125 (2000-07-01), None
patent: WO 0190106 (2001-11-01), None
Hesselgesser et al., J. Biol. Chem. 1998, 273(25): 15687-15692.*
U.S. Appl. No. 60/386,670, filed Jun. 4, 2002, Pfizer Limited.
U.S. Appl. No. 60/449,064, filed Feb. 20, 2003, Pfizer Limited.
Berge, et. al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, 1977, 1-19, vol. 66, No. 1.
Bungaard, H. “Design of Prodrugs”, Elsevier Press., 1985, Amsterdam, New York, Oxford.
Cascieri, M., et. al., “The Chemokine/Chemokine Receptor Family: Potential and Progess for Therapeutic Intervention,” Current Opinion in Chemical Biology, 2000, 4:420-427, vol. 4, No. 4.
Combadiere, et. al., “Cloning and Functional Expression of CC CKR5, a Human Monocyte CC Chemokine Receptor Selective for MIP-α, MIP-1β, and RANTES,” Journal of Leukocyte Biology, 1996, 147-152, vol. 60.
Connor, et. al., “Vpr is Required for Efficient Replication of Human Immunodeficiency Virus Type-1 in Mononuclear Phagocytes,” Virology, 1995, 935-944, vol. 206.
Demitrov, et. al., “Microculture Assay for Isolation of Human Immunodeficiency Virus Type 1 and for Titration of Infected Peripheral Blood Mononuclear Cells,” Journal of Clinical Microbiology, 1990, 734-737, vol. 28, No. 4.
Greene, T., et. al., “Protection for the Amino Group,” Protective Groups in Organic Synthesis, 3rdedition, John Wiley and Sons, 1999, 494-653.
March, Advanced Organic Chemistry, 4thedition, John Wiley and Sons, 1992, 652.
Basford Patricia Ann
Stephenson Peter Thomas
Taylor Stefan Colin John
Wood Anthony
Agouron Pharmaceuticals , Inc.
Huang Evelyn Mei
Hutchinson Keith D.
Richardson Peter C.
Zielinski Bryan C.
LandOfFree
Tropane derivatives useful in therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tropane derivatives useful in therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tropane derivatives useful in therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3510808